HOME >> BIOLOGY >> NEWS
OHSU studying drug for bone-deforming disorder

PORTLAND, Ore. - Jimmy Fox isn't typical of a person with the genetic, "brittle bone" disorder osteogenesis imperfecta (OI). He lifts weights almost daily, participates in grueling wheelchair races, chops wood and enjoys hunting in rough backcountry.

Still, Fox, who owns a busy combination grocery store-gun shop in Cloverdale, Ore., is eager to participate in an Oregon Health & Science University-led study of a drug that may help reduce the debilitating effects of OI, an inherited disorder characterized by weak bones that break easily. People with the most severe forms of OI have short stature, can suffer hundreds if not thousands of fractures in a lifetime, and are confined to a wheelchair.

"I didn't think it could do me any harm," Fox, 40, said of the study. He has a less-severe form of OI, allowing him to be more mobile - he walks on his hands when he's not in his wheelchair - and suffer fewer fractures than many others with the disorder. Fox had both of his legs amputated when he was 18 due to continued fracturing. "The study might do me some good, so I thought I might as well do it and give it a try. It will help other people."

The alternative is unacceptable to Fox, who acknowledges that his significant upper-body strength has kept many of the disorder's most debilitating effects at bay. "They told me 'If you weren't as active as you are, you would be totally screwed up by now.' To be honest, that's what really swayed me to do this."

The study, headed by Eric Orwoll, M.D., professor of medicine (endocrinology, diabetes and clinical nutrition) and director of the Bone and Mineral Unit, OHSU School of Medicine, is examining the effectiveness of the synthesized parathyroid hormone, teriparatide, in increasing bone mass and improving bone structure in adults affected by OI. Teriparatide, derived from the human parathyroid gland, is manufactured and sold by Eli Lilly and Co. under the brand name FORTEO.

FORTEO already is appr
'"/>

Contact: Jonathan Modie
modiej@ohsu.edu
503-494-8231
Oregon Health & Science University
18-May-2006


Page: 1 2 3

Related biology news :

1. UVa researcher studying disease that cripples newborns
2. Stem cells provide new tool for studying disease and identifying ALS drugs
3. Sandia researchers take new approach to studying how cells respond to pathogens
4. Researchers make progress in studying genetic traits of India-born populations
5. Disappearing nest egg: Researcher studying declining numbers of macaws
6. Berkeley lab life scientists are leaders in team to detect cancer by studying proteins in the blood
7. Breakthrough offers new tool for studying degenerative disease
8. New tools developed for studying neurodegenerative brain disorders
9. NYUS Childress demonstrates tool for studying hovering flight at international science meeting
10. MRI best tool for studying intricate nerves in dogs
11. U. of Colorado researchers hunting down, studying new microorganisms

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OHSU studying drug for bone deforming disorder

(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
(Date:4/20/2015)... FOSTER CITY, Calif. , April 20, 2015 /PRNewswire/ ... with InterpretOmics Pvt. Ltd. to provide an integrated Big ... analysis of all biomarkers collected in the context of ... the needs of precise or multi-targeted drug candidates, stratified ... efficacy and disease progression free survival. ...
(Date:4/20/2015)... Portage Biotech Inc. ("Portage" or "the Company") (OTC Market: ... that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. (PPL) ... of its proprietary human-derived CPP sequences and a cargo ... NFkB signalling even if administered when the BBB is ... brain barrier (BBB) in mice was studied and was ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited to ... and Drug Administration (FDA) inspection and received no observations ... compliance inspection, as based upon 21CFR Parts 210 and ... and was granted NAI (no action indicated) status. The ... Manufacturing Practice (GMP) quality system required by the regulatory ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2
Cached News: